Skip to main content
Wizlink Consulting Pte Ltd
Menu
  • About
  • Our Services
  • Our Clients
  • Our Partners
  • News
  • Contact
    • Careers
Wizlink Consulting Pte Ltd
Press enter to begin your search
Close Search

Quiz for AYR webinar


  • Your Answer is Incorrect

    Answer with Detailed explanation

    Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is diagnosed in about 50% of patients diagnosed with SSc and is associated with a high mortality rate. As a substantial number of patients with SSc-ILD are asymptomatic, screening for SSc-ILD is of paramount importance. As the sensitivity and diagnostic accuracy of chest radiographs in SSc-ILD are very low, they are not indicated for ILD screening.

    Lung function test is an important tool in the initial assessment and follow-up of patients with SSc-ILD. However, as the lung function test's false-negative rate is substantial, it cannot rule out SSc-ILD. Consequently, a current evidence-based European consensus statement suggests performing a screening HRCT in all patients with SSc-ILD at baseline.

    Reference:

    • Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12.
    • Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61.
    • Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83.

    By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria


  • Your Answer is Correct

    Answer with Detailed explanation

    Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is diagnosed in about 50% of patients diagnosed with SSc and is associated with a high mortality rate. As a substantial number of patients with SSc-ILD are asymptomatic, screening for SSc-ILD is of paramount importance. As the sensitivity and diagnostic accuracy of chest radiographs in SSc-ILD are very low, they are not indicated for ILD screening.

    Lung function test is an important tool in the initial assessment and follow-up of patients with SSc-ILD. However, as the lung function test's false-negative rate is substantial, it cannot rule out SSc-ILD. Consequently, a current evidence-based European consensus statement suggests performing a screening HRCT in all patients with SSc-ILD at baseline.

    Reference:

    • Hoffmann-Vold AM, et al. Arthritis Rheumatol. 2015;67(8):2205-12.
    • Sulimann YA et al. Arthritis Rheumatol. 2015;67(12):3256-61.
    • Hoffmann-Vold AM et al. Lancet Rheumatology. 2020;2:e71-e83.

    By Prof Helmut Prosch, Associate Professor of Radiology, University of Vienna, Austria

© 2023 Wizlink Consulting Pte Ltd. Terms & Conditions | Privacy Policy

Close Menu
  • About
  • Our Services
  • Our Clients
  • Our Partners
  • News
  • Contact
    • Careers